Psoriasis

Previous inquiries into the associations between sleep disorders were limited by small sample sizes, according to researchers.

Biologic-naïve status and higher inflammation predict rapid skin clearance with psoriasis biologics, while palmoplantar disease may limit response.

The FDA's March 2026 approvals marked significant regulatory milestones across multiple disease states.

Combining traditional dermatopathology with PCR-based molecular testing improves diagnostic accuracy in differentiating eczema from psoriasis, particularly in ambiguous cases.

A phase 3 clinical trial found that the ustekinumab biosimilar CT-P43 demonstrated equivalent efficacy, safety, and immunogenicity to reference ustekinumab in patients with moderate to severe plaque psoriasis.

Icotrokinra is the first and only interleukin-23–targeted oral peptide approved for plaque psoriasis.

Phase 3 trials show deucravacitinib, the first TYK2 inhibitor approved for adults with active psoriatic arthritis (PsA), improves both joint and skin symptoms.

Safety profiles, efficacy, and lifestyle factors inform shared decision-making and help optimize biologic selection in inflammatory disease management.

A new psoriasis severity tool called G2-PASE showed a strong correlation with PASI, potentially offering a simpler assessment for clinical practice.

Tildrakizumab at 100-mg and 200-mg doses showed long-term effectiveness for managing psoriasis in challenging areas in a real-world study.

Chronic skin diseases like psoriasis and AD are linked to high smoking and other addiction rates, highlighting the need for integrated psychosocial support.

A validated XGBoost model identifies psoriasis patients at high hyperglycemia risk, supporting personalized care through a user-friendly web calculator.

With new treatments, environmental insights, and evolving views on comorbidity shaping patient care, this is the most-viewed psoriasis content of 2025.

Zasocitinib met all primary and secondary end points, showing rapid PASI 75 responses and high rates of skin clearance vs placebo and apremilast.

The ustekinumab biosimilar DMB-3115 matched reference therapy in efficacy and safety for moderate to severe plaque psoriasis, according to a phase 3 trial.

A large review identifies 70 safety signals for bimekizumab, confirming known risks while revealing previously unreported adverse events.

Adalimumab significantly reduces activity limitations and boosts work ability and quality of life in patients with psoriasis.

Exposure to antibiotics is linked to higher risk of biologic discontinuation in psoriasis, potentially through gut microbiota changes.

Guselkumab significantly inhibited structural joint damage and improved symptoms in active PsA through 48 weeks.

New findings reveal high rates of depression, anxiety, and sleep issues in individuals with psoriatic arthritis and palmoplantar psoriasis.

Tildrakizumab maintained a favorable safety profile through 208 weeks in patients with psoriatic arthritis, with no new safety signals reported.

More than 50% of patients with psoriasis are eligible for systemic treatment, and nearly 90% would switch to an effective oral therapy with a favorable safety profile.

Higher body size and metabolic factors are linked to worse psoriasis and lower biologic treatment success.

A 16-week Mediterranean diet reduced psoriasis severity and improved metabolic health in patients with mild to moderate psoriasis.